News
We send the latest information from SMC Laboratories.
Introduction of STAM™ model for pre-clinical studies for liver cancer
Today, we give you a brief introduction to our proprietary NASH-HCC model (STAM™ model). The STAM™…
Study on the efficacy of dietary supplements in the STAM™ model published in BMJ Open Gastroenterology
SMC is proud to announce that GN Corporation Co. Ltd (JPN) has published the results of their study using our …
Drug Efficacy Study in the STAM™ Model Published in Biomedicines.
SMC is proud to announce that MRM Health (BEL) has published the results of their study using our STAM™ …
Introducing our new skin disease model: Imiquimod (IMQ)-induced psoriasis model
We are pleased to announce that we have expanded our preclinical model lineup by including the “Imiquimo…
Introduction of MAFLD criteria and the disease model
Today, we would like to introduce metabolic dysfunction-associated fatty liver disease (MAFLD), a new concept …
SMC client receives award for presentation on study of NASH diagnosis at 40th annual meeting of JSLSM
Today, I would like to share with you some wonderful and exciting news! Recently, a client of ours from the Na…
Introduction of our Primary sclerosing cholangitis (PSC) mice model
Today, I would like to give you a brief introduction into primary sclerosing cholangitis (PSC), as well as our…
The effect of the gut-liver axis dysfunction in liver disease
Today, I would like to introduce the relationship between Nonalcoholic steatohepatitis (NASH) and the gut. &nb…
Drug Efficacy Study in the STAM™ Model Published in Cells
SMC is proud to announce that Cellaïon (BEL) has published the results of their study using our STAM&trad…
Drug Efficacy Study in the STAM™ Model Published in Gene
SMC is proud to announce that TSUMURA & CO. (JPN) has published the results of their study using our…